## EFX: Equifax, Inc. - XLI: Industrials

### Executive Summary

VALUE thesis: PEG 1.02 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($208.66)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Equifax secures 27 new patents in second half of 2025**
- Source: Investing.com India | 20251217T220833 | Somewhat-Bullish | Relevance: 100%
- Equifax Inc. (NYSE:EFX) has secured 27 new patents in the second half of 2025, bringing its total for the year to 62, with 20 of these supporting its artificial intelligence initiatives. The company currently holds nearly 700 issued or pending patents globally, with over 320 focused on responsible AI. Despite a 19.5% stock decline over the past year, Equifax maintains impressive gross profit margins of 57.1% and is considered slightly undervalued by InvestingPro analysis.

**2. Equifax Secures 27 New Patents in the Second Half of 2025**
- Source: Yahoo Finance | 20251217T212000 | Bullish | Relevance: 100%
- Equifax secured 27 new patents in the second half of 2025, contributing to a total of 62 patents for the year. A significant 20 of these patents are related to artificial intelligence (AI), bolstering Equifax's EFX.AI strategy and accelerating the development of cloud-based, AI-enabled solutions. These innovations aim to create new financial opportunities for consumers and enhance decision-making through advanced data and analytics.

**3. Morgan Stanley Cuts Equifax (NYSE:EFX) Price Target to $280.00**
- Source: MarketBeat | 20251217T161445 | Neutral | Relevance: 100%
- Morgan Stanley reduced its price target for Equifax (NYSE:EFX) to $280.00 from $290.00, while maintaining an "overweight" rating, suggesting a potential 27.6% upside. Despite this, insider selling has been observed with CEO Mark W. Begor and other insiders liquidating significant shares. The credit services provider reported strong Q3 earnings, beating analyst expectations, and has received a consensus "Moderate Buy" rating from analysts.

**4. Morgan Stanley Adjusts Equifax Price Target to $280 From $290, Maintains Overweight Rating**
- Source: marketscreener.com | 20251217T140020 | Neutral | Relevance: 100%
- Morgan Stanley has adjusted its price target for Equifax (EFX) to $280, down from $290, while reiterating an "Overweight" rating on the stock. This update comes with a published time on December 17, 2025, at 08:57 am EST. The report from MT Newswires indicates a professional analyst's re-evaluation of the financial services company.

**5. Equifax (EFX) Expands Patent Portfolio with Strong Focus on AI**
- Source: GuruFocus | 20251217T220833 | Somewhat-Bullish | Relevance: 99%
- Equifax (EFX) has significantly expanded its patent portfolio in 2025 by acquiring 62 new patents, with 20 specifically focused on artificial intelligence innovations. This strategic move enhances the company's competitive edge in AI-driven data analytics and risk modeling. Despite strong financial health indicators, the company faces some warning signs related to asset growth outpacing revenue and insider selling.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Morgan Stanley | $280 | $290 | -3% |
| 2025-12-08 | BMO Capital | $234 | $245 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Morgan Stanley | main | Overweight |
| 2025-12-08 | BMO Capital | main | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.90M) |
| Sells | 5 ($1.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+2.1%)
- Capital Internationa: 8.5% (-0.4%)
- Blackrock Inc.: 7.5% (+1.4%)
- Price (T.Rowe) Assoc: 4.9% (+1.0%)
- Harris Associates L.: 4.8% (+14.2%)

### Key Risks

1. Long-term trend broken: trading 9.5% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.0B |
| Beta | 1.59 |
| 52W Range | $199.98 - $281.07 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 24.8 |
| Current P/E | 28.8 |
| YoY Growth | 16.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 0.5pp (needs >4.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (1.42), confirming momentum. RSI neutral at 57. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.52% (CS: 74) | Neutral |
| RSI_14 | 57.3 | Neutral |
| MACD Histogram | 1.42 | Bullish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 1.014x | Above |
| vs SMA200 | 0.905x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $219.38
- **Stop Loss:** $208.66 (4.9% risk)
- **Target:** $240.82 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 66
- **Position Value:** $14,479.08
- **Portfolio %:** 14.48%
- **Risk Dollars:** $712.50
- **Risk Per Trade:** 0.71%
- **Modifiers:** L1 95% | L2 75% | Combined 0.71x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-05 (Est: $2.04)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.94 | $2.04 | +5.3% |
| 2025Q2 | $1.92 | $2.00 | +4.1% |
| 2025Q1 | $1.40 | $1.53 | +9.0% |
| 2024Q4 | $2.10 | $2.12 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*